IQV IQVIA HOLDINGS INC.
Services-Commercial Physical & Biological Research · NYSE · SEC CIK 1478242 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.8%
TTM net income YoY8.7%
TTM EPS YoY13.1%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR7.7%
Margins
Gross margin33.1%
Operating margin12.8%
Net margin8.1%
FCF margin12.0%
EBITDA margin19.9%
Returns
ROE21.7%
ROA4.7%
ROIC (approx.)9.3%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets77.7%
Debt / equity2.41x
Current ratio0.83x
Interest coverage2.83x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $16.31B | $15.40B |
| Cost of revenue | $10.88B | $10.03B |
| Gross profit | $5.43B | $5.38B |
| SG&A expense | $2.00B | $1.99B |
| Operating income | $2.18B | $2.20B |
| Interest expense | $729.00M | $670.00M |
| Pretax income | $1.59B | $1.67B |
| Income tax | $252.00M | $301.00M |
| Net income | $1.36B | $1.37B |
| EBITDA | $3.33B | $3.32B |
| EPS (basic) | 7.91 | 7.57 |
| EPS (diluted) | 7.84 | 7.49 |
| Weighted avg. shares (diluted) | 173.50M | 183.40M |
| Balance sheet | ||
| Cash & equivalents | $1.98B | $1.70B |
| Short-term investments | $161.00M | $141.00M |
| Receivables | $3.40B | $3.20B |
| Current assets | $6.25B | $5.83B |
| PP&E, net | $533.00M | $535.00M |
| Goodwill | $16.62B | $14.71B |
| Intangibles | $4.96B | $4.50B |
| Total assets | $29.94B | $26.90B |
| Current liabilities | $8.34B | $6.96B |
| Short-term debt | $1.84B | $1.15B |
| Long-term debt | $13.88B | $12.84B |
| Total debt | $15.72B | $13.98B |
| Total liabilities | $23.31B | $20.83B |
| Shareholders' equity | $6.50B | $6.07B |
| Net debt | $13.74B | $12.28B |
| Shares outstanding | 169.60M | 176.10M |
| Cash flow statement | ||
| Operating cash flow | $2.65B | $2.72B |
| Capital expenditure | $603.00M | $602.00M |
| Free cash flow | $2.05B | $2.11B |
| Investing cash flow | -$2.31B | -$1.44B |
| Financing cash flow | -$150.00M | -$878.00M |
| Depreciation & amortization | $1.14B | $1.11B |
| Stock-based compensation | $247.00M | $206.00M |
| Share buybacks | $1.24B | $1.35B |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.